TNFRSF9 and cancer: Briefly, the mechanism of 4-1BB agonism in the treatment of cancer is believed to be dependent on and mediated by the activation of multiple anti-tumoral immune pathways, primarily in CD8+ T cells that infiltrate the tumors.